Back to search

University of Saskatchewan

Angiotensin converting enzyme (ACE) inhibitors and cough

Abstract

dc:description.abstract

Individuals taking ACE inhibitors are at increased risk of developing a dry, nonproductive cough. The frequency of cough has been reported from as low as 0.5% to as high as 37%. Although the cough is often mild and infrequent, it can, in some patients, be very severe and incapacitating interfering with daily activities and sleep. Onset of the cough varies from 24 hours to several months after taking the first dose of the ACE inhibitor. Resolution of the cough occurs within 24 hours to 4 weeks after withdrawal of the ACE inhibitor. Because studies have included a small number of patients, the accuracy of the reported of cough as a side effect has been questioned. The present study was designed to determine incidence rate and prevalence rate of cough in a of hypertensive patients taking ACE inhibitors. prevalence the population A secondary objective was to identify risk factors which might predispose individuals to the development of cough. Individuals recruited from the family medicine unit and the hypertension clinic at the Royal University Hospital, Saskatoon were asked to complete two questionnaires, approximately 8 weeks apart. Questionnaires elicited information on past and current drug use, other diseases, smoking history, etc. Data on drug use and clinical conditions were also obtained from physicians' records. To maximize the validity of the study, statistical analyses were done on hypertension clinic patients only. At the time of administration of questionnaire 2,129 (68.6%) respondents were taking an ACE inhibitor (treatment group for prevalence determination) and 59 (31.4%) were controls, receiving other anti-hypertensive drugs. Eleven of the 188 respondents (5.9%) had been prescribed an ACE inhibitor for the first time (incidence group). In the present investigation, the incidence rate of cough in individuals who were started on an ACE inhibitor was 72.7%. The likelihood of developing a cough after beginning therapy with an ACE inhibitor was 10.5 times that of controls. However, the 95% CI (4.37,25.42) was wide reflecting the small sample size of the study. The prevalence rate of cough in individuals taking an ACE inhibitor, alone or in combination with other antihypertensive therapy, was 39.7% (PRR: 23.41, 95% CI: 7.41,73.93) in questionnaire 1 and 51.9% (PRR: 6.13, 95% CI: 3.28,11.47) in questionnaire 2. In those patients who were treated with ACE inhibitors and no other antihypertensive medication (i.e., monotherapy) the prevalence rate of cough was 31.6% (PRR: questionnaire 1 questionnaire 2. 18.95, 95% and 46.7% CI: (PRR: 14.88, 5.51, 39.91) 95% CI: in 2.15,14.10) in Of those individuals taking an ACE inhibitor, the prevalence rates of cough were similar for females (PR:53.1%) and males (PR: 51.3%); prevalence rate ratios and 95% CI were comparable. Age did not confound the association between cough and ACE inhibitors. Stratification of individuals into groups, <50y and ≥50y, produced identical prevalence rates of cough; differences in PRR were considered random due to the small sample size. Using data from questionnaire 2, individuals on the long-acting ACE inhibitors, enalapril and lisinopril, had a slightly higher prevalence rate of cough than those on captopril. Even though the prevalence rate ratios (PRR) were greater for the two longer-acting ACE inhibitors, the overlapping 95% confidence intervals mean a larger sample size is necessary before any firm conclusions can be made. Concurrent use of diuretics, calcium channel blockers, or other factors such as smoking, presence of a cold, NSAID use, and diabetes, did not confound the association between ACE inhibitors and cough. A larger sample size is necessary to confirm these results. In the present study, individuals who reported a cough also complained of a tickling sensation in the back of the throat. The cough was most commonly described as dry and nonproductive. No difference in cough or tickling severity was noted between the specific ACE inhibitors. Based on prevalence data, the majority of patients (49.3%) with a cough reported 1 to 3 cough episodes per day. A small subset of the ACE inhibitor users with a cough (3.0%) reported it to be continuous. Approximately half of the population felt the cough was time-related with the worst episodes occurring in the evening, overnight and early morning. The majority of patients (73.1%) did not self- medicate or seek treatment for their cough. Of those patients who did try to treat their cough, most reported that temporary relief of the cough could be obtained by sipping on water or sucking on lozenges or hard candies. Narcotics, cough suppressants, and/or expectorants, were minimally effective. Medication or home remedies were unsuccessful in relieving the cough in 7 (10.4%) of the prevalence cases. Four patients (3.0%) discontinued therapy with an ACE inhibitor due to the incapacitating effects of the cough. The present study confirms the association between cough and concurrent use of ACE inhibitors and indicates that the side effect -- cough -- may be more common than previously reported. The only definitive treatment for the cough, to date, is discontinuation of the offending ACE inhibitor. However, in certain individuals, cough may improve with a reduction in the ACE inhibitor dose. A larger sample size is required to identify cough risk factors as well as evaluate the efficacy of medications in alleviating the annoying cough. It is important that health care professionals are aware of this common side effect and its implications for patient care.

Degree

thesis:*
Name thesis:degree_name
Master of Science (M.Sc.)
Level thesis:degree_level
Masters
Discipline thesis:degree_discipline
Pharmacy
Department thesis:degree_department
Pharmacy and Nutrition
Grantor
University of Saskatchewan
Year dc:date.issued
1992

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Evans, Barbara L
Advisors dc:contributor.advisor
  • Suveges, Linda
  • Wallace, Sylvia
Committee member dc:contributor.committeemember
  • Reeder, Bruce

Subjects

dc:subject × 4

Identifiers

dc:identifier.*
Handle dc:identifier.uri
https://hdl.handle.net/10388/14366

Chain of custody

source
Harvested from
University of Saskatchewan
Base URL
harvest.usask.ca/server/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Evans, Barbara L. Angiotensin converting enzyme (ACE) inhibitors and cough. Masters thesis, University of Saskatchewan, 1992. https://hdl.handle.net/10388/14366